DelveInsight’s, “Moderate To Severe Plaque Psoriasis Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report

• DelveInsight’s Moderate to Severe Plaque Psoriasis Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
• Leading Moderate to Severe Plaque Psoriasis companies such as Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra, and others are evaluating novel Plaque Psoriasis treatment drugs candidate to improve the treatment landscape.
• Key Moderate to Severe Plaque Psoriasis pipeline therapies in various stages of development includes BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202 , DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772, and others.
• The Moderate to Severe Plaque Psoriasis Companies and academics are working to assess challenges and seek opportunities that could influence Moderate to Severe Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Moderate to Severe Plaque Psoriasis.

 

Recent Developmental Activities in the Moderate to Severe Plaque Psoriasis Pipeline

• In November 2021, the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 10, 2022.
• In March 2022, Jansen Research and development announced the initiation of VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp PsO.
• The Janssen Pharmaceutical Companies of Johnson & Johnson in March 2022 announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase III VOYAGE 1 and VOYAGE 2 clinical trials.
• In March 2022, Nimbus Therapeutics initiated a Phase Ib clinical trial of its investigational oral allosteric tyrosine kinase 2 inhibitor, NDI-034858, in patients with moderate-to-severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting. NDI-034858 was observed to be generally well-tolerated and no serious adverse events were observed and no trends of adverse events were noted with increasing drug exposure.
• On April 7, 2022, Meiji Seika Pharma dosed first patient in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with moderate to severe Plaque Psoriasis in the United States and Canada.
• Can-Fite in March 2022 announced completed enrollment in its Phase III Comfort™ study for the treatment of moderate-to-severe plaque psoriasis with 400 patients enrolled across 30 sites in Europe, Israel, and Canada. Topline data are expected in Q2 2022.

 

Request a sample and discover the recent advances in the Moderate to Severe Plaque Psoriasis Treatment @ Moderate to Severe Plaque Psoriasis Pipeline Outlook

 

Moderate to Severe Plaque Psoriasis Overview

Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Those thick, scaly patches that develop on the skin are called plaques (placks). About 80% to 90% of people living with psoriasis get plaques, so they have plaque (plack) psoriasis. It is an autoimmune disease in which skin cells rapidly build up, forming scales and dry, itchy patches that flake off. Scientists don’t yet fully understand the mechanisms behind autoimmune diseases like Moderate to Severe Plaque Psoriasis, but it is believed that a person’s genetics play a central role. Around a third of people with psoriasis have a family history of the disease and evidence of chromosomal mutations on specific locations of a gene (known as PSORS1 through PSORS9).Other causes of Moderate to Severe Plaque Psoriasis, including past infections or toxic exposure, but most are hypothetical at best. Chronic Moderate to Severe Plaque Psoriasis, also known as psoriasis vulgaris, typically appears as raised patches of inflamed skin covered with silvery-white scales (plaques). The plaques are most commonly found on the elbows, knees, scalp, and back. Moderate to Severe Plaque Psoriasis can also affect the nails, causing discoloration, pitting, and even detachment of the nail from the nail bed. Moderate to Severe Plaque Psoriasis can often worsen during an infection, when a person is stressed, or if the skin is injured.

 

Moderate to Severe Plaque Psoriasis Emerging Drugs

BMS-986165: Bristol-Myers Squibb

Deucravacitinib (BMS-986165) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action. Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in psoriasis pathogenesis. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.

AK111: Akeso Biopharma

AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Moderate to Severe Plaque Psoriasis.

 

Moderate to Severe Plaque Psoriasis Pipeline Therapeutics Analysis

There are approx. 30+ key companies which are developing the therapies for Moderate to Severe Plaque Psoriasis. The companies which have their Moderate to Severe Plaque Psoriasis drug candidates in the most advanced stage, i.e. Pre-Registration, Bristol-Myers Squibb.

 

Find out more about Moderate to Severe Plaque Psoriasis Medications @ Moderate to Severe Plaque Psoriasis Treatment Landscape

 

Moderate to Severe Plaque Psoriasis Therapeutics Assessment

The Moderate to Severe Plaque Psoriasis Pipeline report proffers an integral view of the Moderate to Severe Plaque Psoriasis emerging novel therapies segmented by Stage, Product Type,  Molecule Type,  Mechanism of Action, and Route of Administration.

 

Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report 

• Coverage: Global 
• Moderate to Severe Plaque Psoriasis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Moderate to Severe Plaque Psoriasis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Moderate to Severe Plaque Psoriasis Therapeutics Assessment By Route of Administration: Oral, Parenteral, Topical, Intravitreal, Subretinal
• Moderate to Severe Plaque Psoriasis Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Moderate to Severe Plaque Psoriasis Therapeutics Assessment By Mechanism of Action: TYK2 kinase inhibitors, IL17A protein inhibitors, Interleukin 23 inhibitors, Janus kinase 1,2,3 inhibitors, Sphingosine 1 phosphate receptor agonists, Cell replacements
• Key Moderate to Severe Plaque Psoriasis Companies: Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, and others.
• Key Moderate to Severe Plaque Psoriasis Pipeline Therapies: BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202 , DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772 and others.

 

Dive deep into rich insights for drugs for Plaque Psoriasis, visit @ Moderate to Severe Plaque Psoriasis Clinical Trials

 

 

Table of Content

1. Introduction
2. Executive Summary
3. Moderate to Severe Plaque Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Moderate to Severe Plaque Psoriasis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. BMS-986165: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. AK111: Akeso Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Moderate to Severe Plaque Psoriasis Key Companies
21. Moderate to Severe Plaque Psoriasis Key Products
22. Moderate to Severe Plaque Psoriasis – Unmet Needs
23. Moderate to Severe Plaque Psoriasis – Market Drivers and Barriers
24. Moderate to Severe Plaque Psoriasis – Future Perspectives and Conclusion
25. Moderate to Severe Plaque Psoriasis Analyst Views
26. Moderate to Severe Plaque Psoriasis Key Companies
27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate To Severe Plaque Psoriasis drugs?
• How many Moderate To Severe Plaque Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate To Severe Plaque Psoriasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate To Severe Plaque Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate To Severe Plaque Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

 

For further information on the Moderate to Severe Plaque Psoriasis pipeline therapeutics, reach out to Moderate to Severe Plaque Psoriasis Drugs

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/